SCHEMBL4328894

SCHEMBL4328894

NC(=S)NN=Cc1cc(F)c(N2CCN(CCn3cccc3)CC2)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.43
HTT P42858 1/20 0.36
GAA P10253 6/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
KDM4E B2RXH2 2/20 0.36
MAPT P10636 4/20 0.35
ATM Q13315 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
ALDH1A1 P00352 2/20 0.35
USP2 O75604 1/20 0.35
POLB P06746 1/20 0.34
LMNA P02545 1/20 0.34
MPI P34949 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
GLA P06280 1/20 0.34
RRM2 P31350 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4328890 1.00 MAOB (0.43) MAOBHTTGAAL3MBTL1KDM4E
SCHEMBL4331045 0.84 MAOB (0.46) MAOBGAAL3MBTL1KDM4EMAPT
SCHEMBL4331046 0.84 MAOB (0.46) MAOBGAAL3MBTL1KDM4EMAPT
SCHEMBL4455405 0.83 ALDH1A1 (0.47) MAOBHTTGAAL3MBTL1KDM4E
SCHEMBL4455409 0.83 ALDH1A1 (0.47) MAOBHTTGAAL3MBTL1KDM4E
SCHEMBL4325311 0.81 L3MBTL1 (0.52) MAOBGAAL3MBTL1KDM4ENPSR1
SCHEMBL4331768 0.81 ALDH1A1 (0.48) MAOBGAAL3MBTL1KDM4EMAPT
SCHEMBL4331762 0.81 ALDH1A1 (0.48) MAOBGAAL3MBTL1KDM4EMAPT
SCHEMBL4325307 0.81 L3MBTL1 (0.52) MAOBGAAL3MBTL1KDM4ENPSR1
SCHEMBL4324284 0.80 MAOB (0.50) MAOBHTTGAAL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAOB 2762/4885HTT 2994/4885GAA 2113/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAOB 3093/4885HTT 3282/4885GAA 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.